PMID- 27816486
OWN - NLM
STAT- MEDLINE
DCOM- 20180322
LR  - 20180322
IS  - 1989-7286 (Electronic)
IS  - 0365-6691 (Linking)
VI  - 92
IP  - 3
DP  - 2017 Mar
TI  - Treat-and-extend approach with aflibercept: Effects on different subtypes of 
      age-related choroidal neovascularisation.
PG  - 112-119
LID - S0365-6691(16)30187-3 [pii]
LID - 10.1016/j.oftal.2016.09.005 [doi]
AB  - OBJECTIVE: To describe functional/morphological outcomes of treat-and-extend 
      (TAE) with aflibercept in different subtypes of neovascularizations (CNV) 
      secondary to exudative age-related macular degeneration (AMD). METHODS: 
      Retrospective study was conducted on 30 eyes of 30 patients treated with 
      2 mg-aflibercept according to a TAE protocol. Examinations included best 
      corrected visual acuity (BCVA), number of injections, and visits needed. A 
      quantitative/qualitative analysis was also performed with fluorescein angiography 
      and spectral-domain optical coherence tomography (SD-OCT) at baseline, and at 3, 
      6, and 12 months. RESULTS: BCVA significantly improved from 0.61+/-0.26 logMAR to 
      0.38+/-0.34 logMAR. Among the total AMD patients, type 1 CNV was diagnosed in 11 
      eyes (36%), type 2 CNV in 7 eyes (23%), mixed CNV in 5 eyes (16%), and type 3 CNV 
      or retinal angiomatous proliferation (RAP) in 7 eyes (23%). The final mean number 
      of injections was 7.5+/-1.65, 8.71+/-0.76, 7.4+/-0.89, 7.2+/-0.7, and number of visits 
      6.6+/-2.17, 7.89+/-1.46, 5.8+/-1.7, and 7.14+/-1.57, respectively in type 1, type 2, 
      mixed, and type 3 or RAP. There was no difference between the different subtypes 
      of CNV (P>.05). CONCLUSIONS: Aflibercept in TAE is effective for all 
      exudative-AMD subtypes. No significant differences in patient's visual gain, mean 
      number of injections, or number of visits needed were found among the subtypes of 
      CNV.
CI  - Copyright (c) 2016 Sociedad Espanola de Oftalmologia. Publicado por Elsevier 
      Espana, S.L.U. All rights reserved.
FAU - Castro-Navarro, V
AU  - Castro-Navarro V
AD  - Servicio de Oftalmologia, Hospital General Universitario de Valencia, Valencia. 
      Espana; Escuela de Doctorado, Universidad Catolica de Valencia San Vicente 
      Martir, Valencia, Espana. Electronic address: veronicacastronavarro@gmail.com.
FAU - Cervera-Taulet, E
AU  - Cervera-Taulet E
AD  - Servicio de Oftalmologia, Hospital General Universitario de Valencia, Valencia. 
      Espana.
FAU - Montero-Hernandez, J
AU  - Montero-Hernandez J
AD  - Servicio de Oftalmologia, Hospital General Universitario de Valencia, Valencia. 
      Espana.
FAU - Navarro-Palop, C
AU  - Navarro-Palop C
AD  - Servicio de Oftalmologia, Hospital General Universitario de Valencia, Valencia. 
      Espana.
LA  - eng
LA  - spa
PT  - Journal Article
PT  - Observational Study
TT  - Estrategia <<Tratar y Extender>> con aflibercept: efecto en diferentes tipos de 
      neovascularizacion coroidea asociada a la edad.
DEP - 20161102
PL  - Spain
TA  - Arch Soc Esp Oftalmol
JT  - Archivos de la Sociedad Espanola de Oftalmologia
JID - 1304603
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 15C2VL427D (aflibercept)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
SB  - IM
CIN - Arch Soc Esp Oftalmol. 2017 Apr;92(4):193-194. PMID: 28185697
CIN - Arch Soc Esp Oftalmol (Engl Ed). 2018 May;93(5):e29-e30. PMID: 29402496
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/administration & dosage/*therapeutic use
MH  - Choroidal Neovascularization/classification/diagnostic imaging/*drug 
      therapy/etiology
MH  - Female
MH  - Fluorescein Angiography
MH  - Humans
MH  - Intravitreal Injections
MH  - Male
MH  - Receptors, Vascular Endothelial Growth Factor/administration & 
      dosage/*therapeutic use
MH  - Recombinant Fusion Proteins/administration & dosage/*therapeutic use
MH  - Retrospective Studies
MH  - Tomography, Optical Coherence
MH  - Treatment Outcome
MH  - Visual Acuity
MH  - Wet Macular Degeneration/*complications
OTO - NOTNLM
OT  - Aflibercept
OT  - Choroidal neovascularisation
OT  - Choroidal thickness
OT  - Grosor coroideo
OT  - Neovascularizacion coroidea
OT  - Proliferacion angiomatosa retiniana
OT  - Retinal angiomatous proliferation
OT  - Spectral-domain optical coherence tomography
OT  - Tomografia de coherencia optica de dominio espectral
OT  - Tratar y extender
OT  - Treat and extend
EDAT- 2016/11/07 06:00
MHDA- 2018/03/23 06:00
CRDT- 2016/11/07 06:00
PHST- 2016/07/30 00:00 [received]
PHST- 2016/09/13 00:00 [revised]
PHST- 2016/09/19 00:00 [accepted]
PHST- 2016/11/07 06:00 [pubmed]
PHST- 2018/03/23 06:00 [medline]
PHST- 2016/11/07 06:00 [entrez]
AID - S0365-6691(16)30187-3 [pii]
AID - 10.1016/j.oftal.2016.09.005 [doi]
PST - ppublish
SO  - Arch Soc Esp Oftalmol. 2017 Mar;92(3):112-119. doi: 10.1016/j.oftal.2016.09.005. 
      Epub 2016 Nov 2.